# Editorial: Innovative strategies for overcoming resistance in tumor angiogenesis therapies

**Authors:** Peace Mabeta, Vanessa Steenkamp, José Díaz-Chávez

PMC · DOI: 10.3389/fphar.2026.1801844 · Frontiers in Pharmacology · 2026-02-23

## Full-text entities

- **Genes:** SPATA2 (spermatogenesis associated 2) [NCBI Gene 9825] {aka PD1, PPP1R145, tamo}, KCTD10 (potassium channel tetramerization domain containing 10) [NCBI Gene 83892] {aka BTBD28, MSTP028, ULRO61, hBACURD3}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, CTNNB1 (catenin beta 1) [NCBI Gene 1499] {aka CTNNB, EVR7, MRD19, NEDSDV, armadillo}, EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}
- **Diseases:** lung cancer (MESH:D008175), cancer (MESH:D009369), proteinuria (MESH:D011507), NSCLC (MESH:D002289), hypoxia (MESH:D000860), metastasis (MESH:D009362), hypertension (MESH:D006973), toxicities (MESH:D064420), ovarian cancer (MESH:D010051)
- **Chemicals:** platinum (MESH:D010984), bevacizumab (MESH:D000068258), gefitinib (MESH:D000077156)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** L858R

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12968619/full.md

## References

3 references — full list in the complete paper: https://tomesphere.com/paper/PMC12968619/full.md

---
Source: https://tomesphere.com/paper/PMC12968619